ASC4FIRST Trial & Asciminib New FDA Approval: Evaluating Asciminib in First-Line CML Treatment

Author(s):

Jorge Cortes, MD,Stephen A. Strickland, MD, MSCI

Panelists discuss how a clinician seeks guidance on implementing asciminib in first-line chronic myeloid leukemia treatment following its FDA approval, including understanding its trial data and determining appropriate patient selection compared with existing tyrosine kinase inhibitor options.

EP: 1.Evaluating Early Treatment Response in CML: Expert Insights on Monitoring

EP: 2.Interpreting Milestones: Prioritizing the Patient Picture

EP: 3.Managing T315I Mutations in CML: Second Line Treatment Options - Ponatinib & Asciminib

EP: 4.Beyond T315I mutations: When to Consider Ponatinib or Asciminib in CML Second-Line Treatment

EP: 5.Managing Adverse Events: Ponatinib & Asciminib in CML: Expert Approaches

EP: 6.Choosing First-Line TKI Therapy for CML: Expert Approaches to Risk Assessment & Treatment Selection

Now Viewing

EP: 7.ASC4FIRST Trial & Asciminib New FDA Approval: Evaluating Asciminib in First-Line CML Treatment

EP: 8.Key Takeaways: The Current Landscape and Future of CML Care

Video content above is prompted by the following:

Can you tell us about the trial design, key end points, and your impressions of the data?
With the recent FDA approval of asciminib in the first-line (1L) setting, how will you incorporate this into your practice?
- Are there particular patients whom you would consider for asciminib vs first- or second-generation tyrosine kinase inhibitors?
Please share any anticipated similarities or differences in your clinical practice now that asciminib has received FDA approval in the 1L setting.